COVID-19: Page 29


  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    Color targets supply, staffing bottlenecks with updated coronavirus test EUA

    The population health technology company's test uses dry nasal swabs, eliminating the need for the viral transport media that's been in short supply and limited scaling by lab giants Quest and LabCorp.

    By July 28, 2020
  • Image attribution tooltip

    Photo by Getty; photo illustration by Michelle Rock / Medtech Dive

    Image attribution tooltip
    Deep Dive

    Coronavirus testing hits a wall: Where do we go from here?

    As LabCorp and Quest are backlogged in delivering molecular test results, some public health officials are calling for a shift in testing approach from slow and accurate to fast and good enough to meet demand.

    By July 27, 2020
  • Image attribution tooltip

    Photo by Getty; photo illustration by Michelle Rock / Medtech Dive

    Image attribution tooltip

    Medtech and COVID-19: 6 months into the public health emergency

    MedTech Dive examines where the industry stands with testing and the future of those emergency use-authorized diagnostics, as well as how it's adapting to a rebound in elective surgeries and various supply chain challenges.

    July 27, 2020
  • Image attribution tooltip

    Photo by Getty; photo illustration by Michelle Rock / Medtech Dive

    Image attribution tooltip
    Deep Dive

    Medtechs reboot with patients, providers after elective surgeries bottom out

    Recovery of procedures critical to device companies came quicker than many in the industry expected. Now, device makers are adapting as business volumes normalize and COVID-19 continues to spread.

    By Maria Rachal • July 27, 2020
  • Image attribution tooltip

    Photo by Getty; photo illustration by Michelle Rock / Medtech Dive

    Image attribution tooltip

    How COVID-19 is challenging and changing medtech supply chain management

    Four experts share insights on the supply and demand hangups medtechs have been working through during the pandemic, and a few early takeaways the industry can carry forward.

    By Maria Rachal • July 27, 2020
  • Image attribution tooltip

    Photo by Getty; photo illustration by Michelle Rock / Medtech Dive

    Image attribution tooltip

    Diagnostics makers must plan for EUA products to have post-pandemic future

    An extension to the public health emergency formalized a reprieve for emergency use authorizations, but manufacturers should act now if they want products to stay on the market when the crisis ends, compliance experts say.

    By July 27, 2020
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    LabCorp COVID-19 test gets 1st FDA OK for asymptomatic screening

    U.S. regulators simultaneously allowed the LabCorp test to be used in sample pooling, following the first such nod to a Quest Diagnostics test a week ago.

    By July 27, 2020
  • United States $100 bills
    Image attribution tooltip
    "Money" by Ervins Strauhmanis is licensed under CC BY 2.0
    Image attribution tooltip

    COVID-19 diagnostics emerging as prime investment target, SVB analysis shows

    Companies with tech involved in the pandemic response raised $1.3 billion over the first half of the year, with developers of tests and R&D tools enjoying a 62% increase in investment.

    By July 24, 2020
  • Edwards aims for 5% TAVR sales growth in 2020 after seeing demand bounce back

    Quarterly sales came in $25 million above the top end of the device maker's guidance, with 90% of its active sites having done TAVR procedures in May and June. Yet, there are concerns regarding a slowdown in new patient screenings.

    By July 24, 2020
  • HHS Secretary Alex Azar
    Image attribution tooltip
    Peter Ashkenaz, ONC
    Image attribution tooltip

    HHS renews COVID-19 public health emergency

    The extension supported by AdvaMed, the American Clinical Laboratory Association and American Hospital Association takes effect Saturday and opens the door for FDA to keep issuing emergency use authorizations.

    By Shannon Muchmore • July 23, 2020
  • Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    COVID-19 test demand backs 61% jump in Roche molecular diagnostic sales in 2020

    "As far as the molecular diagnostics business is concerned, there is no doubt we will sell anything we can produce over the next half year,” Roche CEO Severin Schwan said on an earnings call with investors. 

    By July 23, 2020
  • Quest Diagnostics building
    Image attribution tooltip
    Courtesy of Quest Diagnostics
    Image attribution tooltip

    Quest says COVID-19 hotspot spikes starting to hit routine testing recovery

    In addition to soaring demand for coronavirus testing, the lab giant's Q2 was helped by gradual improvement in base testing volumes. But recent outbreaks have sent numbers down again in July.

    By July 23, 2020
  • Watchman Flx Left Atrial Appendage Closure Device
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific to begin limited US launch of latest Watchman device

    The medtech hopes the updated version of its high-growth stroke technology will help boost its interventional cardiology unit as elective procedures pick back up.

    By Maria Rachal • July 22, 2020
  • Thermo Fisher rakes in $1.3B in coronavirus-related Q2 revenue

    The company expects momentum to continue in the third quarter after posting springtime results showing a more than 70% jump in its diagnostic and healthcare end market sales fueled by soaring demand for COVID-19 testing.

    By July 22, 2020
  • Medical technicians process specimens at a COVID-19 Community-Based Testing Site at the PNC Bank Arts Center in Holmdel, N.J., March 23, 2020. The testing site, established in partnership with the Fed
    Image attribution tooltip
    Master Sgt. Hecht, Matt. (2020). [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    AdvaMed launches COVID-19 test registry to address shortages

    Created in partnership with Abbott, Roche, Siemens and others, the database is aimed at helping ensure sufficient testing supply by providing weekly state- and national-level updates on the number of tests shipped.

    By July 22, 2020
  • 4 healthcare sticking points as Congress weighs next coronavirus relief bill

    Senate Republicans may limit allocations for testing efforts, as labs struggle to keep up with demand and return results in a timely enough fashion to leverage contact tracing.

    By Rebecca Pifer , Samantha Liss • July 21, 2020
  • NuVasive surprises analysts with sooner-than-expected spine surgery sales rebound

    Preliminary second quarter results show sales were down 30% year over year but were about a third higher than average analyst expectations, adding to evidence of a faster-than-predicted COVID-19 recovery in the medtech sector.

    By July 21, 2020
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    FDA eases rules on viral transport media to boost availability for COVID-19 testing

    In some cases, a dearth of key materials has constricted efforts to widen COVID-19 testing. Now, the agency is allowing commercial manufacturers to ship products without filing a 510(k) or meeting UDI requirements.

    By July 21, 2020
  • As pandemic rages on, hip and knee surgeons lay out elective procedure guidance

    An international group of orthopaedic experts outlined recommended changes to hospital protocols to prevent transmission of COVID-19 when elective procedures resume.

    By July 20, 2020
  • Transmission electron microscopic image of an isolate from the first U.S. case of COVID-19, formerly known as 2019-nCoV. The spherical viral particles, colorized blue, contain cross-section through th
    Image attribution tooltip
    Courtesy of Centers for Disease Control and Prevention
    Image attribution tooltip

    Quidel says its COVID-19 antigen test is now on par with PCR accuracy

    Results suggest the product is more sensitive than a rival test sold by BD. Some analysts say that could help shore up concerns about the faster, point-of-care tests' accuracy. 

    By July 20, 2020
  • Quest Diagnostics 7500 Real Time PCR System
    Image attribution tooltip
    Courtesy of Quest Diagnostics
    Image attribution tooltip

    Quest coronavirus test becomes 1st with FDA OK for sample pooling

    The technique is "not a magic bullet," Quest's chief medical officer said, with demand for its COVID-19 services still overwhelming capacity. However, rival LabCorp said it has reduced its average turnaround time for results.

    By Maria Rachal • July 20, 2020
  • Philips sees double-digit COVID-19 connected care bump amid Q2 sales dip

    Headwinds won out this spring, dragging total sales down 6%. Still, management predicted the return of elective procedures will help tip the balance to growth for the rest of the year.

    By July 20, 2020
  • Quest Diagnostics building
    Image attribution tooltip
    Courtesy of Quest Diagnostics
    Image attribution tooltip

    3 Quest COVID-19 assays get FDA OK for at-home collection via telehealth

    The agency this week granted new emergency use authorizations to three tests, previously granted EUAs, so users can self-collect nasal swab samples while being observed by a healthcare provider remotely.

    By July 17, 2020
  • Thermo Fisher ups Qiagen offer by 10% after investor backlash cites COVID-19 growth

    The acquisition was announced weeks before the U.S. doubled down on its need for widespread coronavirus testing, which provided a big business opportunity for Qiagen that it capitalized on during the second quarter.

    By Maria Rachal • July 16, 2020
  • J&J device sales fell by one-third in Q2, but June rebound drives better 2020 outlook

    Device sales in some areas returned to around 90% of pre-pandemic levels by the end of the quarter, causing J&J to improve its 2020 worst-case scenario for the division by $1.75 billion.

    By July 16, 2020